SCHEMBL6403560

SCHEMBL6403560

Cc1c(NC(=O)c2ccccc2)ccc2nc(N(C)Cc3ccccc3)oc(=O)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.50
CTRB1 P17538 2/20 0.48
MAPT P10636 5/20 0.44
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
ELANE P08246 1/20 0.42
ADORA3 P0DMS8 1/20 0.40
LMNA P02545 3/20 0.40
POLB P06746 2/20 0.40
TP53 P04637 2/20 0.40
ALDH1A1 P00352 3/20 0.39
HTT P42858 2/20 0.39
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
GAA P10253 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497245 0.79 HDAC6 (0.46) HDAC6CTRB1ELANELMNAHTT
SCHEMBL6398072 0.76 CTRB1 (0.51) HDAC6CTRB1MAPTELANELMNA
SCHEMBL6496738 0.76 ELANE (0.59) CTRB1ELANE
SCHEMBL6396933 0.71 CTRB1 (0.50) CTRB1ELANEADORA3
SCHEMBL6401804 0.69 ELANE (0.54) CTRB1ELANEPOLB
SCHEMBL6498375 0.69 CTRB1 (0.68) HDAC6CTRB1ELANEALDH1A1
SCHEMBL6496069 0.69 ELANE (0.50) HDAC6CTRB1MAPTELANELMNA
SCHEMBL6397133 0.67 ABCC1 (0.57) HDAC6MAPTHDAC3HDAC1HDAC2
SCHEMBL19029241 0.67 HDAC6 (1.00) HDAC6HDAC3HDAC1HDAC2
SCHEMBL6506565 0.67 ELANE (0.53) HDAC6CTRB1ELANEALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6806269-B1 EFFECTIVE AT LOWER CONCENTRATIONS; SUCH AS 6-(((1,1-DIMETHYL-ETHOXY)CARBONYL)AMINO)-5-METHYL-2-(METHYL(PHENYLMETHYL) -AMINO)-4H-3,1-BENZOXAZIN-4-ONE G. D. SEARLE & COP 2004-10-19 US claimed
US-20050032795-A1 2-Amino-benzoxazinones for the treatment of herpes simplex virus G.D. SEARLE & CO. (US) 2005-02-10 US disclosed
US-6806269-B1 EFFECTIVE AT LOWER CONCENTRATIONS; SUCH AS 6-(((1,1-DIMETHYL-ETHOXY)CARBONYL)AMINO)-5-METHYL-2-(METHYL(PHENYLMETHYL) -AMINO)-4H-3,1-BENZOXAZIN-4-ONE G. D. SEARLE & COP 2004-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032795-A1 2-Amino-benzoxazinones for the treatment of herpes simplex virus GABBR1, GABBR2, EBNA1BP2 HDAC6 1999/4885CTRB1 3288/4885MAPT 3656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.